Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-28T17:21:22.526Z Has data issue: false hasContentIssue false
  • English
  • Français

The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro

Published online by Cambridge University Press:  06 April 2009

C. S. Davies ,
M. Pudney ,
J. C. Nicholas  and
R. E. Sinden
C. S. Davies*
Affiliation:
Molecular and Cellular Parasitology Research Group, Department of Pure and Applied Biology, Imperial College, Prince Consort Road, London SW7 2BB
M. Pudney
Affiliation:
Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS
J. C. Nicholas
Affiliation:
Molecular and Cellular Parasitology Research Group, Department of Pure and Applied Biology, Imperial College, Prince Consort Road, London SW7 2BB
R. E. Sinden
Affiliation:
Molecular and Cellular Parasitology Research Group, Department of Pure and Applied Biology, Imperial College, Prince Consort Road, London SW7 2BB
*
*Department of Anatomy and Developmental Biology, University College London, Gower Street, London WC1E 6BT.
Get access Rights & Permissions [Opens in a new window]

Summary

The causal prophylactic activity of the novel hydroxynaphthoquinone, S66C80, was assessed against the exo-erythrocytic (EE) stages of Plasmodium berghei cultured in the human hepatoma cell line, HepG2. 566C80 was found to be highly active as an inhibitor of EE development and was more active than the established causal prophylactic pyrimethamine. A 566C80 concentration of 1·85 × 10−9 M, added 3 h after sporozoite invasion, reduced the numbers of EE forms visible at 48 h by 50%, while the equivalent concentration of pyrimethamine was 1·95 × 10−8 M.

Keywords

Plasmodium bergheiexo-erythrocytic stageshydroxynaphthoquinonepyrimethamine.
Type
Research Article
Information
Parasitology , Volume 106 , Issue 1 , January 1993 , pp. 1 - 6
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Ager, A. L. (1984). Rodent malaria models. In Antimalarial Drugs I (ed. Peters, W. & Richards, W. H. G.), pp. 225–264. Berlin: Springer-Verlag.Google Scholar
Berberian, D. A., Slighter, R. G. & Feele, H. W. (1968). Causal prophylactic effect of menoctone (a new hydroxynaphthoquinone) against sporozoite-induced Plasmodium berghei infection in mice. Journal of Parasitology 54, 1181–9.CrossRefGoogle ScholarPubMed
Davidson, D. E., Ager, A. L., Brown, J. L., Chapple, F. E., Whitmire, R. E. & Rossan, R. N. (1981). New tissue schizontocidal antimalarial drugs. Bulletin of the World Health Organization 59, 463–79.Google ScholarPubMed
Davies, C. S., Pudney, M., Matthews, P. J. & Sinden, R. E. (1989 a). The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats. Acta Leidensia 58, 115–28.Google ScholarPubMed
Davies, C. S., Suhribier, A. S., Winger, L. A. & Sinden, R. E. (1989 b). Improved techniques for the culture of the liver stages of Plasmodium berghei and their relevance to the study of causal prophylactic drugs. Acta Leidensia 58, 97–113.Google Scholar
Eriksson, B., Courtier, B., Bjorkman, A., Miltgen, F. & Mazier, D. (1991). Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoelii yoelii in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene 85, 725–6.CrossRefGoogle ScholarPubMed
Fawaz, G. & Haddad, F. S. (1951). The effect of lapinone (m-2350) on Plasmodium vivax infections in man. American Journal of Tropical Medicine and Hygiene 31, 569–71.CrossRefGoogle Scholar
Fisk, T. L., Millet, P., Collins, W. E. & Nguyen-Dinh, P. (1989). In vitro activity of antimalarial compounds on the exoerythrocytic stages of Plasmodium cynomolgi and P. knowlesi. American Journal of Tropical Medicine and Hygiene 40, 235–9.CrossRefGoogle ScholarPubMed
Fry, M. & Pudney, M. (1992). Site of action of the antimalarial hydroxy-naphthoquinone, 2-[trans-(4′-chlorophenyl)cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80). Biochemical Pharmacology 43, 1545–53.CrossRefGoogle Scholar
Gregory, K. G. & Peters, W. (1970). The chemotherapy of rodent malaria, IX. Causal prophylaxis, part I. A method for testing drug action on exo-erythrocytic stages. Annals of Tropical Medicine and Parasitology 64, 15–24.CrossRefGoogle Scholar
Hammond, D. J., Burchell, J. R. & Pudney, M. (1985). Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxyl-1, 4-napthoquinone in vitro. Molecular and Biochemical Parasitology 14, 97–109.CrossRefGoogle Scholar
Hill, J. (1975). The activity of some antibiotics and long-acting compounds against the tissue stages ofPlasmodium berghei. Annals of Tropical Medicine and Parasitology 69, 421–7.CrossRefGoogle Scholar
Hollingdale, M. R., Collins, W. E., Campbell, C. C. & Schwartz, A. L. (1985 a). In vitro culture of 2 populations (dividing and non-dividing) of exoerythrocytic parasites of Plasmodium vivax. American Journal of Tropical Medicine and Hygiene 34, 216–22.CrossRefGoogle Scholar
Hollingdale, M. R., Leland, P. & Sigler, C. (1985 b). In vitro cultivation of the exoerythrocytic stage of Plasmodium berghei in irradiated hepatoma cells. American Journal of Tropical Medicine and Hygiene 34, 21–3.CrossRefGoogle ScholarPubMed
Hudson, A. T. (1984). Lapinone, menoctone, hydroxyquinolinequinones and similar structures. In Antimalarial Drugs II (ed. Peters, W., & Richards, W. H. G.), pp. 343–361. Berlin: Springer-Verlag.CrossRefGoogle Scholar
Hudson, A. T., Dickins, M., Ginger, C. D., Gutteridge, W. E., Hodich, T., Hutchinson, D. B. A., Pudney, M., Randall, A. W., & Latter, V. S., (1991). 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs under Experimental and Clinical Research 17, 427–35.Google ScholarPubMed
Hudson, A. T., Pether, M. J. & Randall, A. W. (1986).In vitro activity of 2-cycloalkyl-3-hydroxy-1, 4-naphthoquinones against Theileria, EimeriaandPlasmodia species. European Journal of Medicinal Chemistry 21, 271–5.Google Scholar
Hudson, A. T., Randall, A. W., Fry, M., Ginger, C. D., Hill, B., Latter, V. S., McHardy, N. & Williams, R. B. (1985). Novel antimalarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology 90, 45–55.CrossRefGoogle ScholarPubMed
Mazier, D., Beaudoin, R. L., Mellouk, S., Druilhe, P., Texier, B., Trosper, T., Miltgen, T., Landau, I., Paul, C., Brandicourt, O., Guguen-Guillouzo, C., Langlois, P. & Gentilini, M. (1985). Complete development of hepatic stages of Plasmodium falciparum in vitro. Science 277, 440–2.CrossRefGoogle Scholar
Mazier, D., Collins, W. E., Mellouk, S., Andrysiak, P. M., Berbiguier, N., Campbell, G. H., Miltgen, F., Bertolotti, R., Langlois, P. & Gentilini, M. (1987). Plasmodium ovale: in vitro development of hepatic stages. Experimental Parasitology 64, 393–400.CrossRefGoogle ScholarPubMed
Mazier, D., Landau, L., Druilhe, P., Miltgen, F., Gugen-Guillouzo, C., Baccam, D., Baxter, I., Chigot, J. P. & Gentilini, M. (1984). Cultivation of the liver forms of Plasmodium vivax in human hepatocytes. Nature, London 307, 367–9.CrossRefGoogle ScholarPubMed
Meis, J. F. G. M., Verhave, J. P., Meuwissen, J. H. E. T., Jap, P. H. K., Princen, H. M. G. & Yap, S. K., (1984). Fine structure of Plasmodium berghei exoerythrocytic forms in cultured primary hepatocytes. Cell Biology International Reports 8, 755–65.CrossRefGoogle Scholar
Mellouk, S., Berbiguier, N., Druilhe, P., Sedegah, M., Galey, B., Yuan, L., Leef, M., Charoenvit, Y., Paul, C., Hoffman, S. & Beaudoin, R. (1990) Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bulletin of the World Health Organization 68(Suppl),52–9.Google Scholar
Mellouk, S., Green, S. J., Nancy, C. A. & Hoffman, S., (1991). IFN-γ inhibits the development of Plasmodium berghei exoerythrocytic stages by an L-arginine-dependent effector mechanism. Journal of Immunology 146, 3971–6.CrossRefGoogle ScholarPubMed
Mellouk, S., Maheshwari, R. K., Rhodes-Feuillette, A., Beaudoin, R. L., Berbiguier, N., Matile, H., Miltgen, F., Landau, I., Pied, S., Chigot, J. P., Friedman, R. M. & Mazier, D. (1987). Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. Journal of Immunology 139, 4192–5.CrossRefGoogle ScholarPubMed
Millet, P., Collins, W. E., Aikawa, M., Cochrane, A. H. & Nguyen-Dinh, P. (1990). Use of non-human primate hepatocytes for in vitro study of the pre-erythrocytic stages of malaria parasites. Bulletin of the World Health Organization 68(Suppl),60–5.Google ScholarPubMed
Millet, P., Collins, W. E., Fisk, T. L. & Nguyen-Dinh, P. (1988). In vitro cultivation of exoerythrocytic stages of the human parasite Plasmodium malariae. American Journal of Tropical Medicine and Hygiene 38, 470–3.CrossRefGoogle Scholar
Millet, P., Jiang, J.-B., Lun, Z.-R., Bray, R. S., Canning, E. U. & Landau, I. (1987). In vitro development of schizonts of Plasmodium cynomolgi bastianelli in Macaca rhesus hepatocytes. (In French.) Annales de Parasitologic Humaine et Comparée 62, 5–7.CrossRefGoogle Scholar
Millet, P., Landau, I., Baccam, D., Miltgen, F., & Peters, W. (1985). Cultivation of exo-erythrocytic schizonts of rodent Plasmodium in hepatocytes: a new experimental model for chemotherapy of malaria. (In French.) Comptes Rendus des Seances de L'Académic des Sciences 301, 403–6.Google ScholarPubMed
Most, H. & Montuori, W. A. (1975). Rodent systems (Plasmodium berghei–Anopheles stephensi) for screening compounds for potential causal prophylaxis. American Journal of Tropical Medicine and Hygiene 24, 179–82.CrossRefGoogle ScholarPubMed
Peters, W. (1987). Chemotherapy and Drug Resistance in Malaria, vols 1 and 2, London: Academic Press.Google Scholar
Peters, W. Davies, E. E. & Robinson, B. L. (1975). The chemotherapy of rodent malaria. XXIII. Causal prophylaxis, part II: Practical experience with Plasmodium yoelii nigeriensis in drug screening. Annals of Tropical Medicine and Parasitology 69, 311–28.CrossRefGoogle ScholarPubMed
Schmidt, L. H., Rossan, R. N., Fradkin, R., Woods, J., Schulemann, W. & Kratz, L. (1966). Studies on the antimalarial activity of 1, 2-demethoxy-4-(bidiethylaminoethyl)-amino-5-bromo benzene. Bulletin of the World Health Organization 34, 783–8.Google Scholar
Sinden, R. E., Sughribie, A., Davies, C. S., Fleck, S. L., Hodivala, K. & Nicholas, J. C. (1990). The development and routine application of high-density exoerythrocytic-stage cultures of Plasmodium berghei. Bulletin of the World Health Organization 68(Suppl.),115–25.Google ScholarPubMed
Smith, J. E., Meis, J. F. G. M., Ponnudurai, T., Verhave, J. P. & Moshage, H. J. (1984). In vitro culture of the exoerythrocytic stages of Plasmodium falciparum in adult human hepatocytes. Lancet 2, 757–8.CrossRefGoogle Scholar
Stahel, E., Mazier, M., Guillouzo, A., Miltegen, F., landau, I., Mellouk, S., Beaudoin, R. L., Langlois, P. & Gentilini, M. (1988). Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. American Journal of Tropical Medicine and Hygiene 39, 236–40.CrossRefGoogle ScholarPubMed
Suhrbier, A., Janse, C., Mons, B., Fleck, S. L., Nicholas, J. C., Davies, C. S. & Sinden, R. E. (1987). The Complete development in vitro of the vertebrate phase of the mammalian parasite Plasmodium berghei. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 907–9.CrossRefGoogle ScholarPubMed
World Health Organization (1973). Chemotherapy of malaria and resistance to antimalarials. World Health Organization, Technical Report Series no. 529, 70.Google Scholar